Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.15 USD | +3.66% | +7.03% | +50.85% |
04-25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
04-24 | Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study | MT |
Sales 2024 * | 321M 25.71B | Sales 2025 * | 606M 48.55B | Capitalization | 3.96B 317B |
---|---|---|---|---|---|
Net income 2024 * | -149M -11.93B | Net income 2025 * | 30M 2.4B | EV / Sales 2024 * | 16.9 x |
Net Debt 2024 * | 1.46B 117B | Net Debt 2025 * | 1.28B 102B | EV / Sales 2025 * | 8.63 x |
P/E ratio 2024 * |
-23.7
x | P/E ratio 2025 * |
136
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | +3.66% | ||
Current month | +50.85% | ||
Current year | +50.85% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 01/11/18 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 31/01/20 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 15/06/22 |
Helga Zharov
LAW | General Counsel | 57 | 30/04/20 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 01/11/18 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 14.15 | +3.66% | 248,476 |
25/04/24 | 13.65 | +0.81% | 65,564 |
24/04/24 | 13.54 | +1.04% | 191,089 |
23/04/24 | 13.4 | +0.53% | 195,834 |
22/04/24 | 13.33 | +0.83% | 184,812 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALVO Stock
- ALVO Stock